Eyepoint Pharmaceuticals brings latest advances in retinal science to CTS Retina 2026

Eyepoint Pharmaceuticals brings latest advances in retinal science to CTS Retina 2026
Eyepoint to unveil retinal research

Eyepoint Pharmaceuticals announced its participation in the upcoming CTS Retina 2026 conference, set to take place in Las Vegas.

On June 13th, Dr. Ashkan M. Abbey and Dr. Tarek S. Hassan are scheduled to present the company’s most recent research and progress in treatments for retinal diseases. The event is expected to spotlight innovative approaches and emerging science in ophthalmology. Further details about the presentation and specific findings are anticipated as the conference date approaches.

Eyepoint has previously launched campaigns aimed at developing new treatments for severe retinal conditions such as DME, with activities highlighted during Mens Health Month in June. The company continues to focus research and innovation at its Northbridge facility to create therapies for patients affected by retinal diseases, as detailed in earlier reports on pipeline progress. The ongoing work sets the stage for the latest findings to be presented at the upcoming conference.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.